Trial Profile

An Open Label Study to Evaluate the Efficacy and Tolerability of Erenumab in the Management of Persistent Redness and Flushing in Rosacea

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erenumab (Primary)
Indications Rosacea
Focus Therapeutic Use
Acronyms STOP ROS Study

Most Recent Events

18 Dec 2021 Status changed from recruiting to completed.
09 Jun 2020 Planned End Date changed from 1 Mar 2021 to 1 Aug 2021.
09 Jun 2020 Planned primary completion date changed from 30 Jun 2020 to 1 Mar 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com